Back to today’s briefing

Story perspectives

FDA Approves Sephience: New Hope for PKU Patients

7/30/2025

50 12

Summary

Story summary

The U.S. FDA has granted approval for PTC Therapeutics' Sephience, a groundbreaking oral treatment for phenylketonuria (PKU), a rare genetic disorder that disrupts amino acid breakdown. Following promising trial results, Sephience is set to transform the lives of approximately 58,000 individuals worldwide. The drug is also awaiting approval in Japan and Brazil.

1 of 1

Story summary

The U.S. FDA has granted approval for PTC Therapeutics' Sephience, a groundbreaking oral treatment for phenylketonuria (PKU), a rare genetic disorder that disrupts amino acid breakdown. Following promising trial results, Sephience is set to transform the lives of approximately 58,000 individuals worldwide. The drug is also awaiting approval in Japan and Brazil.